US FDA proposes streamlined biosimilar drug study, testing requirements
MLex Summary: The US Department of Health and Human Services issued a statement regarding the Food and Drug Administration's new proposed "major updates" which would streamline biosimilar drug studies and reduce...To view the full article, register now.
Already a subscriber? Click here to view full article